Keybanc analyst Paul Knight maintains Repligen (NASDAQ:RGEN) with a Overweight and raises the price target from $210 to $220.
Keybanc Maintains Overweight on Repligen, Raises Price Target to $220
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.